Insulin-like growth factor I: A potential neuroprotective compound for the treatment of acute ischemic stroke?

Stroke

Volumn 40, Issue 4, 2009, Pages

  Kooijman, Ron ^a   Sarre, Sophie ^a   Michotte, Yvette ^a   Keyser, Jacques De ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Cerebral stroke; Insulin like growth factor I; Ischemia

Indexed keywords

SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; NEUROPROTECTIVE AGENT;

APOPTOSIS; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; NERVOUS TISSUE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TISSUE REGENERATION; ACUTE DISEASE; ANIMAL; DISEASE MODEL; HUMAN; STROKE;

ACUTE DISEASE; ANIMALS; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; HUMANS; INSULIN-LIKE GROWTH FACTOR I; NEUROPROTECTIVE AGENTS; STROKE;

EID: 65249096594     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.528356     Document Type: Review

References (59)

1. Gropen TI, Gagliano PJ, Blake CA, Sacco RL, Kwiatkowski T, Richmond NJ, Leifer D, Libman R, Azhar S, Daley MB. Quality improvement in acute stroke: the New York State Stroke Center Designation Project. Neurology. 2006;67:88-93.
2. De Keyser J, Suiter G, Luiten PG. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends Neurosci. 1999;22:535-540.
3. Young AR, Ali C, Duretete A, Vivien D. Neuroprotection and stroke: time for a compromise. J Neurochem. 2007;103:1302-1309.
4. Cimino M, Gelosa P, Gianella A, Nobili E, Tremoli E, Sironi L. Statins: multiple mechanisms of action in the ischemic brain. Neuroscientist. 2007;13:208-213.
5. Kooijman R. Regulation of apoptosis by insulin-like growth factor (IGF)-I. Cytokine Growth Factor Rev. 2006;17:305-323.
6. Sjogren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, LeRoith D, Tornell J, Isaksson OG, Jansson JO, Ohlsson C. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA. 1999;96:7088-7092.
7. Trejo JL, Llorens-Martin MV, Torres-Aleman I. The effects of exercise on spatial learning and anxiety-like behavior are mediated by an IGF-I-dependent mechanism related to hippocampal neurogenesis. Mol Cell Neurosci. 2008;37:402-411.
8. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23:824-854.
9. Russo VC, Gluckman P, Feldman EL, Werther GA. The insulin-like growth factor system and its pleiotropic functions in the brain. Endocr Rev. 2005;26:916-943.
10. D'Ercole AJ, Ye P, O'Kusky JR. Mutant mouse models of insulin-like growth factor actions in the central nervous system. Neuropeptides. 2002; 36:209-220.
11. Vincent AM, Mobley BC, Hiller A, Feldman EL. IGF-I prevents glutamate-induced motor neuron programmed cell death. Neurobiol Dis. 2004;16:407-416.
12. Matsuzaki H, Tamatani M, Mitsuda N, Namikawa K, Kiyama H, Miyake S, Tohyama M. Activation of Akt kinase inhibits apoptosis and changes in Bcl-2 and Bax expression induced by nitric oxide in primary hippocampal neurons. J Neurochem. 1999;73:2037-2046.
13. Heck S, Lezoualc'h F, Engert S, Behl C. Insulin-like growth factor-1-mediated neuroprotection against oxidative stress is associated with activation of nuclear factor kappaB. J Biol Chem. 1999;274:9828-9835.
14. Ness JK, Scaduto RC Jr, Wood TL. IGF-I prevents glutamate-mediated bax translocation and cytochrome C release in O4+ oligodendrocyte progenitors. Glia. 2004;46:183-194.
15. Mason JL, Jones JJ, Taniike M, Morell P, Suzuki K, Matsushima GK. Mature oligodendrocyte apoptosis precedes IGF-1 production and oligodendrocyte progenitor accumulation and differentiation during demyeli-nation/remyelination. J Neurosci Res. 2000;61:251-262.
16. Dempsey RJ, Sailor KA, Bowen KK, Tureyen K, Vemuganti R. Stroke-induced progenitor cell proliferation in adult spontaneously hypertensive rat brain: effect of exogenous IGF-1 and GDNF. J Neurochem. 2003;87: 586-597.
17. Espinosa-Jeffrey A, Kumar S, Zhao PM, Awosika O, Agbo C, Huang A, Chang R, De VJ. Transferrin regulates transcription of the MBP gene and its action synergizes with IGF-1 to enhance myelinogenesis in the MD rat. Dev Neurosci. 2002;24:227-241.
18. Zumkeller W. The effect of insulin-like growth factors on brain myeli-nation and their potential therapeutic application in myelination disorders. Eur J Paediatr Neurol. 1997;1:91-101.
19. Chesik D, De KJ, Wilczak N. Insulin-like growth factor system regulates oligodendroglial cell behavior: therapeutic potential in CNS. J Mol Neurosci. 2008;35:81-90.
20. Torres-Aleman I. Insulin-like growth factors as mediators of functional plasticity in the adult brain. Horm Metab Res. 1999;31:114-119.
21. Loddick SA, Liu XJ, Lu ZX, Liu C, Behan DP, Chalmers DC, Foster AC, Vale WW, Ling N, De Souza EB. Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke. Proc Natl Acad Sci USA. 1998;95:1894-1898.
22. Brooker GJ, Kalloniatis M, Russo VC, Murphy M, Werther GA, Bartlett PF. Endogenous IGF-1 regulates the neuronal differentiation of adult stem cells. J Neurosci Res. 2000;59:332-341.
23. Guan J, Williams CE, Skinner SJ, Mallard EC, Gluckman PD. The effects of insulin-like growth factor (IGF)-l, IGF-2, and des-IGF-1 on neuronal loss after hypoxic-ischemic brain injury in adult rats: evidence for a role for IGF binding proteins. Endocrinology. 1996;137:893-898.
24. Johnsen SP, Hundborg HH, Sorensen HT, Orskov H, Tjonneland A, Overvad K, Jorgensen JO. Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. J Clin Endocrinol Metab. 2005;90:5937-5941.
25. Bondanelli M, Ambrosio MR, Onofri A, Bergonzoni A, Lavezzi S, Zatelli MC, Valle D, Basaglia N, Gli Uberti EC. Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome. J Clin Endocrinol Metab. 2006;91:3928-3934.
26. Denti L, Annoni V, Cattadori E, Salvagnini MA, Visioli S, Merli MF, Corradi F, Ceresini G, Valenti G, Hoffman AR, Ceda GP. Insulin-like growth factor 1 as a predictor of ischemic stroke outcome in the elderly. Am J Med. 2004; 117:312-317.
27. van Rijn MJ, Slooter AJ, Bos MJ, Catarino CF, Koudstaal PJ, Hofman A, Breteler MM, van Duijn CM. Insulin-like growth factor I promoter polymorphism, risk of stroke, and survival after stroke: the Rotterdam study. J Neurol Neurosurg Psychiatry. 2006;77:24-27.
28. Banks WA. Denial versus dualism: the blood-brain barrier as an interface of the gut-brain axis. Endocrinology. 2006;147:2609-2610.
29. Reinhardt RR, Bondy CA. Insulin-like growth factors cross the blood-brain barrier. Endocrinology. 1994;135:1753-1761.
30. Strbian D, Durukan A, Pitkonen M, Marinkovic I, Tatlisumak E, Pedrono E, Bo-Ramadan U, Tatlisumak T. The blood-brain barrier is continuously open for several weeks following transient focal cerebral ischemia. Neuroscience. 2008; 153:175-181.
31. Wilczak N, Elting JW, Chesik D, Kema IP, de Keyser J. Intravenous tissue plasminogen activator in patients with stroke increases the bio-availability of insulin-like growth factor-1. Stroke. 2006;37:2368-2371.
32. Guan J, Bennet L, Gluckman PD, Gunn AJ. Insulin-like growth factor-1 and post-ischemic brain injury. Prog Neurobiol. 2003;70:443-462.
33. Liu XF, Fawcett JR, Hanson LR, Frey WH. The window of opportunity for treatment of focal cerebral ischemic damage with noninvasive intranasal insulin-like growth factor-I in rats. J Stroke Cerebrovasc Dis. 2004;13:16-23.
34. Liu XF, Fawcett JR, Thome RG, DeFor TA, Frey WH. Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci. 2001; 187:91-97.
35. Schabitz WR, Hoffmann TT, Heiland S, Kollmar R, Bardutzky J, Sommer C, Schwab S. Delayed neuroprotective effect of insulin-like growth factor-I after experimental transient focal cerebral ischemia monitored with MRI. Stroke. 2001;32:1226-1233.
36. Wang JM, Hayashi T, Zhang WR, Li F, Iwai M, Abe K. Reduction of ischemic damage by application of insulin-like growth factor-1 in rat brain after transient ischemia. Acta Med Okayama. 2001;55:25-30.
37. Wang JM, Hayashi T, Zhang WR, Sakai K, Shiro Y, Abe K. Reduction of ischemic brain injury by topical application of insulin-like growth factor-I after transient middle cerebral artery occlusion in rats. Brain Res. 2000;859:381-385.
38. Rizk NN, Myatt-Jones J, Rafols J, Dunbar JC. Insulin like growth factor-1 (IGF-1) decreases ischemia-reperfusion induced apoptosis and necrosis in diabetic rats. Endocrine. 2007;31:66-71.
39. Zhu W, Fan Y, Frenzel T, Gasmi M, Bartus RT, Young WL, Yang GY, Chen Y. Insulin growth factor-1 gene transfer enhances neurovascular remodeling and improves long-term stroke outcome in mice. Stroke. 2008;39:1254-1261.
40. Shirakura M, Inoue M, Fujikawa S, Washizawa K, Komaba S, Maeda M, Watabe K, Yoshikawa Y, Hasegawa M. Postischemic administration of Sendai virus vector carrying neurotrophic factor genes prevents delayed neuronal death in gerbils. Gene Ther. 2004; 11:784-790.
41. Guan J, Gunn AJ, Sirimanne ES, Tuffin J, Gunning MI, Clark R, Gluckman PD. The window of opportunity for neuronal rescue with insulin-like growth factor-1 after hypoxia-ischemia in rats is critically modulated by cerebral temperature during recovery. J Cereb Blood Flow Metab. 2000;20:513-519.
42. Chen H, Chopp M, Welch KM. Effect of mild hyperthermia on the ischemic infarct volume after middle cerebral artery occlusion in the rat. Neurology. 1991;41:1133-1135.
43. Dirnagl U. Bench to bedside: the quest for quality in experimental stroke research. J Cereb Blood Flow Metab. 2006;26:1465-1478.
44. Donnan GA. The 2007 Feinberg lecture: a new road map for neuropro-tection. Stroke. 2008;39:242.
45. Patel PM, Drummond JC, Cole DJ, Kelly PJ, Watson M. Isoflurane and pentobarbital reduce the frequency of transient ischemic depolarizations during focal ischemia in rats. Anesth Analg. 1998;86:773-780.
46. Warner DS, McFarlane C, Todd MM, Ludwig P, McAllister AM. Sevoflurane and halothane reduce focal ischemic brain damage in the rat. Possible influence on thermoregulation. Anesthesiology. 1993;79: 985-992.
47. Van Hemelrijck A, Vermijlen D, Hachimi-Idrissi S, Sarre S, Ebinger G, Michotte Y. Effect of resuscitative mild hypothermia on glutamate and dopamine release, apoptosis and ischaemic brain damage in the endothelin-1 rat model for focal cerebral ischaemia. J Neurochem. 2003; 87:66-75.
48. Coyle P. Different susceptibilities to cerebral infarction in spontaneously hypertensive (SHR) and normotensive Sprague-Dawley rats. Stroke. 1986;17:520-525.
49. Rizk NN, Rafols J, Dunbar JC. Cerebral ischemia induced apoptosis and necrosis in normal and diabetic rats. Brain Res. 2005; 1053:1-9.
50. Cardona-Gomez GP, Mendez P, DonCarlos LL, Azcoitia I, Garcia-Segura LM. Interactions of estrogens and insulin-like growth factor-I in the brain: implications for neuroprotection. Brain Res Brain Res Rev. 2001;37:320-334.
51. Yan YP, Sailor KA, Vemuganti R, Dempsey RJ. Insulin-like growth factor-1 is an endogenous mediator of focal ischemia-induced neural progenitor proliferation. Eur J Neurosci. 2006;24:45-54.
52. Ranke MB. Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance. Trends Endocrinol Metab. 2005; 16:190-197.
53. Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insen-sitivity. J Clin Endocrinol Metab. 2007;92:902-910.
54. Jabri N, Schalch DS, Schwartz SL, Fischer JS, Kipnes MS, Radnik BJ, Turman NJ, Marcsisin VS, Guler HP. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients. Diabetes. 1994;43:369-374.
55. Clemmons DR, Moses AC, Sommer A, Jacobson W, Rogol AD, Sleevi MR, Allan G. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Horm IGF Res. 2005;15:265-274.
56. Malozowski S, Tanner LA, Wysowski D, Fleming GA. Growth hormone, insulin-like growth factor I, and benign intracranial hypertension. N Engl J Med. 1993;329:665-666.
57. Pan W, Kastin AJ. Interactions of IGF-1 with the blood-brain barrier in vivo and in situ. Neuroendocrinology. 2000;72:171-78.
58. Schwab S, Spranger M, Krempien S, Hacke W, Bettendorf M. Plasma insulin-like growth factor I and IGF binding protein 3 levels in patients with acute cerebral ischemic injury. Stroke. 1997;28:1744-1748.
59. Liu XF, Fawcett JR, Thorne RG, Frey WH. Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusion. Neurosci Lett. 2001;308:91-94.